ECRONICON OPEN ACCESS

EC NEUROLOGY
Review Article

Unraveling the Complexity of Autoimmune Disorders in the Peripheral Nervous System (PNS)

Ahed J Alkhatib[1,2,3]*

[1]*Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan*

[2]*International Mariinskaya Academy, Department of Medicine and Critical Care, Department of Philosophy, Academician Secretary of Department of Sociology, Jordan*

[3]*Cypress International Institute University, Texas, USA*

***Corresponding Author:** Ahed J Alkhatib, Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan.

Received: April 17, 2023; **Published:** May 22, 2023

Abstract

Autoimmune antibodies directed against components of peripheral nervous system (PNS) make different autoimmune disorders such as Myasthenia gravis. The main objective of the present study was to review the literature regarding PNS autoimmune disorders. We have reviewed the literature through searching the appropriate research engines such as PUBMED, Google, Google scholar, and Sciencedirect. The peripheral nervous system, also known as the PNS, is a network of nerves that connects the brain and spinal cord to the rest of the body. The PNS is also known as the autonomic nervous system. Autoimmune disorders that affect the PNS can cause a wide variety of neurological symptoms, some of which include tingling, numbness, and weakness in the muscles. Myasthenia gravis, Guillain-Barre syndrome, and chronic inflammatory demyelinating polyneuropathy (CIDP) are all examples of autoimmune disorders that can affect the peripheral nervous system. The immune system makes a mistake and attacks the myelin sheath or the neuromuscular junction, which results in nerve damage and dysfunction. These disorders are caused by this error. A variety of immunosuppressive drugs, plasma exchange, and intravenous immunoglobulin are all potential treatments for this condition.

Keywords: *PNS; Autoimmune Disorders; Neurological Symptoms; Muscle Weakness; Numbness*

Introduction

Autoimmune disorders are caused by the immune system attacking the body's own cells and tissues in error, which can lead to damage and dysfunction [35]. Because the immune system can attack the myelin sheath that insulates nerve fibers or the nerve cells themselves, the peripheral nervous system (PNS) is especially susceptible to autoimmune disorders. Autoimmune disorders have the potential to affect any component of the nervous system, including both the central nervous system (CNS) and the peripheral nervous system (PNS). Because the immune system can target either the myelin sheath that surrounds and insulates nerve fibers or the nerve cells themselves, the peripheral nervous system is especially susceptible to autoimmune attacks [1].

This can result in a wide variety of neurological symptoms, some of which include tingling, numbness, and weakness. In this article, we will discuss some of the most common autoimmune disorders that affect the PNS, as well as their symptoms and potential treatments [2,3].

Myasthenia gravis

Both myasthenia gravis and Lambert-Eaton syndrome are autoimmune diseases that affect the neuromuscular junction. Myasthenia gravis is characterized by autoantibodies that are directed against the post-synaptic acetylcholine receptor or muscle specific tyrosine kinase. Lambert-Eaton syndrome is characterized by autoantibodies that are directed against pre-synaptic voltage gated calcium channels. Myasthenia gravis is one of the most well-known examples of an autoimmune disease, and its autoimmunity has been demonstrated beyond a reasonable doubt to be the cause of the condition [4,5]. There is a significant amount of circumstantial evidence suggesting that autoimmune disease is the root cause of a variety of conditions affecting skeletal muscle and peripheral nerves, despite the fact that the evidence is inconclusive.

Guillain-Barre syndrome (GBS)

Guillain-Barré Syndrome (also known as GBS) is an extremely uncommon autoimmune disorder that affects the myelin sheath of peripheral nerves. This condition causes muscle weakness and paralysis. According to the National Institute of Neurological Disorders and Stroke (NINDS), approximately one to two people out of every one hundred thousand people in the general population are diagnosed with GBS each year in the United States [1].

In most cases, a viral or bacterial infection, such as Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, or the Zika virus, is the cause of GBS. Because of the infection, the immune system attacks the myelin sheath, which is a protective covering that surrounds nerves and enables them to send signals effectively. This assault on the myelin sheath causes inflammation and damage to the nerves, which in turn results in a wasting away of the muscles and eventual paralysis [6].

Tingling and weakness in the legs are typically the first symptoms of GBS, but these symptoms can rapidly spread to involve other parts of the body such as the arms and the upper body. Due to the fact that the muscles that are responsible for speaking, swallowing, and breathing may also be affected, additional symptoms may include difficulty with these functions. In extreme circumstances, patients might need the assistance of mechanical ventilation to keep them breathing [7].

GBS is considered a serious medical emergency and requires patients to be hospitalized. Patients diagnosed with severe GBS are typically admitted to the intensive care unit (ICU) in order to receive monitoring and supportive care, as stated in a study that was published in the Journal of Clinical Neuromuscular Disease [8]. Immunoglobulin therapy or plasmapheresis are two potential treatments for GBS. These procedures aim to remove antibodies from the patient's blood that are damaging the myelin sheath [9]. Patients diagnosed with GBS who receive these treatments may experience a reduction in the severity and duration of their symptoms, as well as an improvement in their overall outcomes [10].

In conclusion, GBS is an uncommon autoimmune disorder that can have serious complications, some of which may even pose a risk to the patient's life. If you experience any symptoms of GBS, it is imperative that you seek medical attention as soon as possible because early diagnosis and treatment can significantly improve outcomes.

Chronic inflammatory demyelinating polyneuropathy (CIDP)

Chronic inflammatory demyelinating polyneuropathy, also known as CIDP, is a rare autoimmune disorder that affects the myelin sheath of peripheral nerves. This condition causes limbs to experience a loss of sensation as well as a deterioration in the strength of the muscles. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) affects approximately 1 - 8 people per 100,000 in the general population each year in the United States, as reported by the National Institute of Neurological Disorders and Stroke (NINDS) [1].

The chronic inflammatory demyelinating polyneuropathy (CIDP) is a degenerative disorder that can cause symptoms such as tingling, numbness, and weakness in the hands and feet, as well as difficulty walking. As the disease advances, these symptoms may spread to other

parts of the body, such as the arms and legs, and they may make it difficult to carry out routine tasks. Fatigue is another symptom that some people who have CIDP may experience, which can have a significant negative impact on their quality of life [11].

It is not known for certain what causes CIDP; however, it is believed that an abnormal immune response is what sets off the condition. CIDP is characterized by the presence of autoantibodies that attack the myelin sheath, resulting in inflammation and damage to the nerves, as stated in a study that was published in the *Journal of Neurology, Neurosurgery, and Psychiatry*. CIDP is characterized by the presence of autoantibodies that attack the myelin sheath [12].

Immunosuppressive therapy, plasmapheresis, or immunoglobulin therapy are all potential treatments for chronic inflammatory demyelinating polyneuropathy (CIDP). These treatments intend to bring the inflammation level down and stop any further nerve damage from occurring. Patients with CIDP who received immunosuppressive therapy, according to a study that was published in the *Journal of Neurology*, had significant improvements in their muscle strength and disability scores [13,14].

In conclusion, chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder that can have a significant impact on the quality of life of a patient. Early diagnosis and treatment are essential for preventing further damage to the nerves and improving the prognosis for patients who have chronic inflammatory demyelinating polyneuropathy (CIDP).

Multifocal motor neuropathy (MMN)

A rare form of autoimmune disease known as multifocal motor neuropathy (MMN) is characterized by damage to the motor nerves of the peripheral nervous system. It is characterized by progressive weakness and wasting of the muscles, most noticeably in the hands and arms, but it can also affect the legs and the muscles that control breathing. The immune system attacks the myelin sheath that surrounds motor nerves, which results in impaired nerve conduction and muscle weakness in patients with multiple myeloma (MMN) [15].

Because the symptoms of multiple myeloma neuropathy (MMN) are similar to those of other neuromuscular disorders, such as amyotrophic lateral sclerosis (ALS) and chronic inflammatory demyelinating polyneuropathy (CIDP), making a diagnosis of MMN can be difficult [16]. Electromyography (EMG) is a diagnostic test that can help differentiate multiple myeloma neuropathy (MMN) from other disorders by showing characteristic signs of conduction block. Conduction block is defined as a decrease in the amplitude of a nerve signal that occurs when the nerve is stimulated at different points along its length [17,18].

The treatment for MMN focuses on lowering the severity of the attack that the immune system has on the motor nerves. It has been demonstrated that immunoglobulin therapy, which consists of the infusion of immunoglobulin antibodies, is effective in enhancing both the muscular strength and function of patients who have been diagnosed with MMN. Plasmapheresis, a process that filters potentially dangerous antibodies out of the blood, is another treatment option for MMN that has shown promise. Nevertheless, these treatments are not a cure for the disorder, and the benefits they provide may only be short-term. As a result, the maintenance of muscle strength and function may necessitate on-going plasmapheresis or periodic infusions of immunoglobulin as part of the long-term management of MMN [19,20].

In conclusion, multiple myelodystrophies are a rare autoimmune disorder that affects the motor nerves of the peripheral nervous system. This condition causes gradual muscle wasting and weakness as it progresses. Although MMN can be difficult to diagnose, electromyography can be an extremely helpful diagnostic tool. The most effective treatments for this condition are immunoglobulin therapy and plasmapheresis; however, long-term management is required in order to preserve muscle function.

Vasculitic neuropathy

Vasculitic neuropathy is a form of autoimmune disorder that impacts the blood vessels that supply the nerves with blood. This condition can cause nerve damage. It is a very uncommon condition that can manifest on its own or as a symptom of a larger systemic autoim-

mune disease such as rheumatoid arthritis or lupus. The exact cause of this condition is unknown [21]. The condition is characterized by inflammation and damage to the blood vessels that supply the peripheral nerves, which can lead to a wide variety of neurological symptoms. These symptoms can include tingling, numbness, and pain in the extremities [22].

As well as pain and cramping in the muscles, vasculitic neuropathy can cause limb tingling, numbness, and weakness. Vasculitic neuropathy can also cause pain in the muscles. The severity of these symptoms can range widely, and they can manifest in various parts of the body depending on which nerves are being compressed [23].

Clinical testing, laboratory examinations, and nerve biopsies are typically used in conjunction with one another to arrive at a diagnosis of vasculitic neuropathy [24]. The condition is typically treated with a combination of immunosuppressive therapy and corticosteroids, which work together to help reduce inflammation and stop any further nerve damage from occurring [25].

Medications that work to suppress the immune system and reduce inflammation in the blood vessels can be included in immunosuppressive therapy. Some examples of these medications include azathioprine, methotrexate, and cyclophosphamide. In order to alleviate symptoms and help reduce inflammation, corticosteroids like prednisone and similar medications are frequently used. Plasma exchange and intravenous immunoglobulin therapy are two additional treatment options that may be utilized in certain circumstances to assist in the management of symptoms and the reduction of inflammation.

The prognosis for vasculitic neuropathy is not uniform and varies according to the severity of the condition as well as the efficacy of treatment. If the appropriate treatment is received, the symptoms of some cases may completely disappear, while those of others may lead to permanent nerve damage and long-term disability [26].

Sjogren's syndrome

Dry mouth and dry eyes are symptoms of Sjogren's syndrome, an autoimmune disorder that primarily affects the exocrine glands, including the salivary and lacrimal glands. This condition causes the glands to produce insufficient amounts of their respective secretions. However, the condition can also cause neurological symptoms, such as numbness, tingling, and weakness in the limbs, in addition to sensory loss and abnormal reflexes. These neurological symptoms can be caused by the condition [27].

Sjogren's syndrome is characterized by a collection of neurological symptoms that are brought on by inflammation and damage to the peripheral nerves. In severe cases, the condition can cause a disabling neuropathy that can have an effect on both the sensory and motor functions of the body. Clinical evaluation, laboratory tests, and imaging studies are typically all utilized in conjunction with one another to arrive at a diagnosis of Sjogren's syndrome [28].

Eye drops that relieve dry eyes are often used as part of the treatment for Sjogren's syndrome. Medications that increase saliva production, such as pilocarpine, are also an option. In addition, immunosuppressive drugs like corticosteroids, methotrexate, or azathioprine might be prescribed to the patient in order to lessen the inflammation and stop any further nerve damage from occurring [29].

In certain circumstances, intravenous immunoglobulin therapy or plasma exchange may be utilized in order to bring symptom control and inflammatory response under control. Individuals who suffer from Sjogren's syndrome-associated neuropathy may benefit from physical therapy by increasing their strength, improving their balance, and enhancing their coordination.

The prognosis for neuropathy associated with Sjogren's syndrome is variable and is based on the severity of the condition as well as the efficacy of treatment. According to Tobón., *et al*. [30], neurological symptoms can be effectively managed in many cases with the appropriate treatment; however, severe cases can result in permanent nerve damage and long-term disability.

Diagnosis

Because the symptoms of autoimmune disorders affecting the peripheral nervous system (PNS) can be similar to the symptoms of other neurological conditions, it can be difficult to diagnose these diseases. However, for effective treatment and management of these disorders, early and accurate diagnosis is essential [31].

A thorough medical examination, an evaluation of the patient's neurological status, and blood tests to look for particular antibodies are typically required for the diagnostic process. Antinuclear antibodies (ANA), extractable nuclear antigen (ENA) antibodies, anti-double-stranded DNA (dsDNA) antibodies, anti-Ro/La antibodies, and anti-ganglioside antibodies are some of the blood tests that may be performed if an autoimmune disorder is suspected. Other blood tests may also be performed [32].

In order to evaluate nerve function and confirm a diagnosis, electromyography (EMG) and nerve conduction studies (NCS) are two additional tests that may be performed. The electromyogram (EMG) measures the speed and strength of nerve impulses in response to electrical stimulation, whereas the nerve conduction study (NCS) measures how quickly nerve impulses respond to electrical stimulation with a small needle electrode [33].

Other diagnostic procedures, such as magnetic resonance imaging (MRI), nerve biopsy, and cerebrospinal fluid analysis, might also be utilized in order to evaluate nerve damage and eliminate other possible sources of the symptoms [34].

It is essential to keep in mind that receiving a negative test result does not necessarily indicate the absence of an autoimmune disorder. If symptoms continue to exist or get worse, additional testing may be necessary.

Summary

A wide variety of neurological symptoms, such as tingling, numbness, and weakness, can be brought on by autoimmune disorders that affect the peripheral nervous system (PNS). A timely diagnosis and treatment are required to reduce the risk of nerve damage that is permanent and to enhance the patient's quality of life. Plasmapheresis, immunoglobulin therapy, and immunosuppressive therapy are some of the potential treatments for this condition.

Bibliography

1. National Institute of Neurological Disorders and Stroke. Guillain-Barré Syndrome Fact Sheet (2023).
2. Alkhatib AJ. “Autoimmunity and Diseases”. In: The Role of Microbes in Autoimmune Diseases. Springer, Singapore (2022).
3. Alkhatib AJ. The Role of Microbes in Autoimmune Diseases (2022).
4. Toyka KV., *et al*. “Myasthenia gravis: passive transfer from man to mouse”. *Science* 190 (1975): 397-399.
5. Patrick J and Lindstrom J. “Autoimmune response to acetylcholine receptor”. *Science* 180 (1973): 871-872.
6. Wakerley BR and Yuki N. “Infectious and noninfectious triggers in Guillain-Barré syndrome”. *Expert Review of Clinical Immunology* 9.7 (2013): 627-639.
7. Willison HJ., *et al*. “Guillain-Barré syndrome”. *Lancet* 388.10045 (2016): 717-727.
8. Hughes RA., *et al*. “Intravenous immunoglobulin for Guillain-Barré syndrome”. *Cochrane Database of Systematic Reviews* 9 (2014): CD002063.
9. Van Doorn PA., *et al*. “Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome”. *The Lancet Neurology* 7.10 (2008): 939-950.

10. Walgaard C., *et al*. "Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): protocol for a double-blind randomized, placebo-controlled clinical trial". *BMC Neurology* 10 (2010): 106.

11. Gorson KC. "Chronic Inflammatory Demyelinating Polyneuropathy". *Current Treatment Options in Neurology* 18.3 (2016): 14.

12. Mathey EK., *et al*. "Immune-mediated neuropathies: recent developments and possible therapeutic avenues". *Muscle and Nerve* 53.2 (2016): 185-192.

13. Joint Task Force of the EFNS and the PNS. "European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society". *European Journal of Neurology* 17.3 (2010): 356-363.

14. Gorson KC., *et al*. "Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice". *Journal of Peripheral Nervous System* 15.4 (2010): 326-333.

15. National Institute of Neurological Disorders and Stroke. Multifocal Motor Neuropathy Information Page (2020).

16. Multifocal Motor Neuropathy Association About MMN (2023).

17. Van Den Bergh PYK., *et al*. "European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society". *European Journal of Neurology* 20.5 (2013): 796-805.

18. Bromberg MB., *et al*. "Multifocal motor neuropathy: electrodiagnostic features". *Muscle and Nerve* 46.3 (2012): 287-292.

19. Harschnitz O., *et al*. "Long-term efficacy of intravenous immunoglobulin in multifocal motor neuropathy". *Journal of the Peripheral Nervous System* 23.3 (2018): 174-179.

20. Nobile-Orazio E., *et al*. "Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial". *The Lancet Neurology* 14.3 (2015): 269-276.

21. Collins MP. "Vasculitic neuropathy". *Current Opinion in Neurology* 30.5 (2017): 482-488.

22. Collins MP. "Peripheral Neuropathies Associated with Connective Tissue Disease". *Continuum* (2017): 23.

23. Dyck PJ., *et al*. "Chronic inflammatory polyradiculoneuropathy". *Mayo Clinic Proceedings* 50.11 (1975): 621-637.

24. Gwathmey KG., *et al*. "Vasculitic neuropathies". *The Lancet Neurology* 13.1 (2014): 67-82.

25. Lacomis D. "Small fiber neuropathy". *Muscle Nerve* 26.2 (2002): 173-188.

26. Martinez AJ and Gorson KC. "Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go". *Muscle Nerve* 55.6 (2017): 789-796.

27. Birnbaum J., *et al*. "Guidelines for the management of nervous system complications of Sjögren's syndrome". *Annals of the Rheumatic Diseases* 77.6 (2018): 817-828.

28. Carsons SE. "Update on Sjogren Syndrome: From Epidemiology, Diagnosis, and the Main Clinical Features to New Treatment Targets". *Current Rheumatology Reports* 21.4 (2019): 18.

29. Sene D and Isenberg D. "Connective tissue diseases: Sjögren's syndrome". *British Medical Journal* 358 (2017): j97.

30. Tobón GJ., *et al*. "Neurological disorders in primary Sjögren's syndrome". *Autoimmune Disease Symptoms* (2012): 645967.

31. Dalakas MC. "Advances in the diagnosis, pathogenesis and treatment of CIDP". *Nature Reviews Neurology* 7.9 (2011): 507-517.

32. Gorson KC and Ropper AH. "Guillain-Barré Syndrome". In: Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL, editions. Bradley's Neurology in Clinical Practice. 7th edition. Elsevier (2016): 2346-2355.

33. Mahdi-Rogers M., *et al*. "Autoimmune neuropathies". *Practical Neurology* 14.4 (2014): 228-242.

34. Willison HJ., *et al*. "Guillain-Barré syndrome". *Lancet* 388.10045 (2016): 717-727.

35. National Institute of Allergy and Infectious Diseases. Autoimmune disorders (2020).

Volume SP15 2023